Morgan Stanley upgraded Sumitomo Pharma (DNPUF) to Equal Weight from Underweight with a price target of 1,350 yen, up from 550 yen. Orgovyx sales are “on a roll” with U.S. Medicare changes driving growth, says the analyst, who cites strong U.S. sales as the main reason the firm raised its forecasts.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNPUF: